Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025

Boundless Bio, Inc.

2024-Q2 EPS reported -$2.78

Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.
Cash, equivalents, and short-term investments $179.3M as of June 30, 2024.
BBI-355 combo cohort enrollment slower than expected; initial proof-of-concept data now H2 2025.
BBI-825 first patient dosed in April 2024; initial data also expected H2 2025.
Workforce reduced and operations streamlined to extend runway into Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.